Your browser doesn't support javascript.
loading
Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting.
Gendron, Nicolas; Chocron, Richard; Billoir, Paul; Brunier, Julien; Camoin-Jau, Laurence; Tuffigo, Marie; Faille, Dorothée; Teissandier, Dorian; Gay, Juliette; de Raucourt, Emmanuelle; Suner, Ludovic; Bonnet, Corentin; Martin, Anne-Céline; Lasne, Dominique; Ladhari, Chayma; Lebreton, Aurélien; Bertoletti, Laurent; Ajzenberg, Nadine; Gaussem, Pascale; Morange, Pierre-Emmanuel; Le Cam Duchez, Véronique; Viallon, Alain; Roy, Pierre-Marie; Lillo-le Louët, Agnès; Smadja, David M.
Afiliação
  • Gendron N; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Chocron R; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Paris, France.
  • Billoir P; Université de Paris, PARCC, INSERM, Paris, France.
  • Brunier J; Emergency Department, AH-HP, Georges Pompidou European Hospital, Paris, France.
  • Camoin-Jau L; Normandie Univ, UNIROUEN, INSERM Rouen University Hospital, Vascular Hemostasis Unit, Rouen, France.
  • Tuffigo M; CHU-Pellegrin, Laboratory of Hematology, Bordeaux, France.
  • Faille D; AP-HM, CHU Timone, Laboratory of Hematology, Marseille, France.
  • Teissandier D; CHU Angers, Laboratory of Hematology, Angers, France.
  • Gay J; Université de Paris, Laboratory of Vascular Translational Science, INSERM, Paris, France.
  • de Raucourt E; Laboratory of Hematology, AH-HP, Bichat Hospital, Paris, France.
  • Suner L; CHU Clermont-Ferrand, Emergency Medicine Department, Clermont-Ferrand, France.
  • Bonnet C; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Martin AC; Hematology Department, AH-HP, Georges Pompidou European Hospital, Paris, France.
  • Lasne D; Université de Paris, LVTS, INSERM, Paris, France.
  • Ladhari C; Hematology Department, AP-HP, Hôpital Beaujon, Clichy, France.
  • Lebreton A; Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, AP-HP, Hôpital Saint-Antoine, Hématologie Biologique, Paris, France.
  • Bertoletti L; CHU Sud Réunion, Anaestesiology Department, Saint-Pierre, La Réunion, France.
  • Ajzenberg N; Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
  • Gaussem P; Cardiology Department, AH-HP, Georges Pompidou European Hospital, Paris, France.
  • Morange PE; AP-HP, CHU Necker-Enfants Malades, Department of Biogical Hematology, Paris, France.
  • Le Cam Duchez V; CHU Montpellier, Centre Régional de Pharmacovigilance, Montpellier, France.
  • Viallon A; CHU Clermont-Ferrand, Laboratory of Hematology, Clermont-Ferrand, France.
  • Roy PM; Service de Médecine Vasculaire et Thérapeutique, CHU de Saint-Étienne, INSERM, Université Jean-Monnet, INSERM, CHU de Saint-Étienne, Saint-Étienne, France.
  • Lillo-le Louët A; F-CRIN INNOVTE, Saint-Étienne, France.
  • Smadja DM; Université de Paris, Laboratory of Vascular Translational Science, INSERM, Paris, France.
Front Med (Lausanne) ; 7: 599626, 2020.
Article em En | MEDLINE | ID: mdl-33392223
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França